A NEW DIRECTION in Treating Alzheimer's Disease and Parkinson's Disease and Other Neurodegenerative Conditions
Our drug attacks neurodegeneration by improving axonal transport, the information highway of the nerve cell, which has been shown to be the cause of nerve cell degeneration and ultimately death.
With an aging population, neurodegenerative diseases have become one of the world’s largest unmet medical needs. Annovis understands how the brain works and how brain cells die. Nerve cell death is the underlying cause of all neurodegenerative disease in both slow chronic and fast acute injuries to the brain.
We are developing novel treatments for Alzheimer’s Disease (AD), Parkinson’s (PD) and other neurodegenerative diseases. Our lead candidate, ANVS401, simultaneously inhibits the production of multiple neurotoxic brain proteins that have been shown to impair axonal transport and lead to nerve cell death. Specifically, it inhibits the synthesis of amyloid precursor protein (APP), Tau and α-Synuclein. It is distinct from other AD drugs in development, because, unlike many other drugs that attempt to remove one toxic protein, ANVS401 inhibits the toxic proteins before they can form, and it inhibits all the major neurotoxic proteins responsible for AD and PD.